Familial defective apolipoprotein B-100: A review

Journal of Clinical Lipidology

Volumn 10, Issue 6, 2016, Pages 1297-1302

  Andersen, Lars H ^a   Miserez, André R ^b,c   Ahmad, Zahid ^d   Andersen, Rolf L ^a  

^a Lancaster General Health   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Diagene Laboratories Inc   (Switzerland)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

APOB; Familial defective apolipoprotein B 100; Familial hypercholesterolemia; FDB; FH; Hyperlipidemia; Lipid metabolism; Population genetics; R3500Q; R3500 W

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

AUTOSOMAL DOMINANT INHERITANCE; DISORDERS OF LIPID METABOLISM; FAMILIAL DEFECTIVE APOLIPOPROTEIN B 100; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC DISORDER; GEOGRAPHIC DISTRIBUTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; POPULATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; BLOOD; ETHNOLOGY; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; SINGLE NUCLEOTIDE POLYMORPHISM;

APOLIPOPROTEIN B-100; CHOLESTEROL, LDL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, LDL;

EID: 85002141914     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.09.009     Document Type: Review

References (69)

1. 1 Vega, G.L., Grundy, S.M., In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 78 (1986), 1410–1414.
2. 2 Innerarity, T.L., Weisgraber, K.H., Arnold, K.S., et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A 84 (1987), 6919–6923.
3. 3 Soria, L., Ludwig, E., Clarke, H., et al. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A 86 (1989), 587–591.
4. 4 Innerarity, T.L., Mahley, R.W., Weisgraber, K.H., et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31 (1990), 1337–1349.
5. 5 Gaffney, D., Reid, J.M., Cameron, I.M., et al. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol 15 (1995), 1025–1029.
6. 6 Fouchier, S.W., Kastelein, J.J., Defesche, J.C., Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum Mutat 26 (2005), 550–556.
7. 7 Rabes, J.P., Varret, M., Devillers, M., et al. R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia. Arterioscler Thromb Vasc Biol 20 (2000), E76–E82.
8. 8 Boren, J., Ekstrom, U., Agren, B., et al. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem 276 (2001), 9214–9218.
9. 9 März, W., Baumstark, M.W., Scharnagl, H., et al. Accumulation of “small dense” low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J Clin Invest 92 (1993), 2922–2933.
10. 10 Gallagher, J.J., Myant, N.B., The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100. Eur Heart J 115 (1995), 263–272.
11. 11 Schaefer, J.R., Scharnagl, H., Baumstark, M.W., et al. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vasc Biol 17 (1997), 348–353.
12. 12 Fernandez-Higuero, J.A., Etxebarria, A., Benito-Vicente, A., et al. Structural analysis of APOB variants, p. (Arg3527Gln), p. (Arg1164Thr) and p. (Gln4494del), causing familial hypercholesterolaemia provides novel insights into variant pathogenicity. Sci Rep, 5, 2015, 18184.
13. 13 Friedl, W., Ludwig, E.H., Balestra, M.E., et al. Apolipoprotein B gene mutations in Austrian subjects with heart disease and their kindred. Arterioscler Thromb 11 (1991), 371–378.
14. 14 Arnold, K.S., Balestra, M.E., Krauss, R.M., et al. Isolation of allele-specific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 subjects. J Lipid Res 35 (1994), 1469–1476.
15. 15 Miserez, A.R., Schuster, H., Chiodetti, N., et al. Polymorphic haplotypes and recombination rates at the LDL receptor gene locus in subjects with and without familial hypercholesterolemia who are from different populations. Am J Hum Genet 52 (1993), 808–826.
16. 16 Muller, P.Y., Miserez, A.R., Large heterogeneity of mutations in the gene encoding the low-density lipoprotein receptor in subjects with familial hypercholesterolaemia. Atheroscler Suppl 5 (2004), 1–5.
17. 17 Brautbar, A., Leary, E., Rasmussen, K., et al. Genetics of familial hypercholesterolemia. Curr Atheroscler Rep, 17, 2015, 491.
18. 18 Peloso, G.M., Auer, P.L., Bis, J.C., et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet 94 (2014), 223–232.
19. 19 Bersot, T.P., Russell, S.J., Thatcher, S.R., et al. A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder. J Lipid Res 34 (1993), 1149–1154.
20. 20 Shen, H., Damcott, C.M., Rampersaud, E., et al. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the Old Order Amish. Arch Intern Med 170 (2010), 1850–1855.
21. 21 Benn, M., Watts, G.F., Tybjaerg-Hansen, A., et al. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 37 (2016), 1384–1394.
22. 22 Miserez, A.R., Laager, R., Chiodetti, N., et al. High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 35 (1994), 574–583.
23. 23 Miserez, A.R., Muller, P.Y., Familial defective apolipoprotein B-100: a mutation emerged in the mesolithic ancestors of Celtic peoples?. Atherosclerosis 148 (2000), 433–436.
24. 24 Davignon, J., Roy, M., Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a “founder effect”. Am J Cardiol 72 (1993), 6D–10D.
25. 25 Steyn, K., Goldberg, Y.P., Kotze, M.J., et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet 98 (1996), 479–484.
26. 26 Lehrman, M.A., Schneider, W.J., Brown, M.S., et al. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem 262 (1987), 401–410.
27. 27 Exome Aggregation Consortium (ExAC), Cambridge, MA. Available at: http://exac.broadinstitute.org. Accessed July 28, 2016.
28. 28 Chiou, K.R., Charng, M.J., Genetic diagnosis of familial hypercholesterolemia in Han Chinese. J Clin Lipidol 10 (2016), 490–496.
29. 29 Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. Available at: http://evs.gs.washington.edu/EVS/. Accessed July 28, 2016.
30. 30 Miserez, A.R., Keller, U., Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 15 (1995), 1719–1729.
31. 31 Pimstone, S.N., Defesche, J.C., Clee, S.M., et al. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 17 (1997), 826–833.
32. 32 Marduel, M., Carrie, A., Sassolas, A., et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat 31 (2010), E1811–E1824.
33. 33 Ejarque, I., Real, J.T., Martinez-Hervas, S., et al. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population. Transl Res 151 (2008), 162–167.
34. 34 Tybjaerg-Hansen, A., Steffensen, R., Meinertz, H., et al. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 338 (1998), 1577–1584.
35. 35 Ejarque, I., Civer, M., Francisco Ascaso, J., et al. [Identification and characterization of the first Spanish familial ligand-defective apolipoprotein B homozygote]. Med Clin (Barc) 116 (2001), 138–141.
36. 36 Ceska, R., Vrablik, M., Horinek, A., Familial defective apolipoprotein B-100: a lesson from homozygous and heterozygous patients. Physiol Res 49:Suppl 1 (2000), S125–S130.
37. 37 März, W., Ruzicka, C., Pohl, T., et al. Familial defective apolipoprotein B-100: mild hypercholesterolaemia without atherosclerosis in a homozygous patient. Lancet, 340, 1992, 1362.
38. 38 Loggen, U., Boden, A., Baron, H., et al. Apolipoprotein B-100 gene mutations and cholesterol control in German patients. Eur Heart J 166 (2003), 411–412.
39. 39 Benlian, P., de Gennes, J.L., Dairou, F., et al. Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100. Hum Mutat 7 (1996), 340–345.
40. 40 Rubinsztein, D.C., Raal, F.J., Seftel, H.C., et al. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb 13 (1993), 1076–1081.
41. 41 deCampo, A., Schallmoser, K., Schmidt, H., et al. A novel splice-site mutation in intron 7 causes more severe hypercholesterolemia than a combined FH-FDB defect. Eur Heart J 157 (2001), 524–525.
42. 42 Brusgaard, K., Jordan, P., Hansen, H., et al. Molecular genetic analysis of 1053 Danish individuals with clinical signs of familial hypercholesterolemia. Clin Genet 69 (2006), 277–283.
43. 43 Damgaard, D., Larsen, M.L., Nissen, P.H., et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Eur Heart J 180 (2005), 155–160.
44. 44 Chmara, M., Wasag, B., Zuk, M., et al. Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations. J Appl Genet 51 (2010), 95–106.
45. 45 Widhalm, K., Dirisamer, A., Lindemayr, A., et al. Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations. J Inherit Metab Dis 30 (2007), 239–247.
46. 46 Fisher, E., Gross, W., Marz, W., High prevalence of FDB3500 mutation in the Swiss population. Eur Heart J 153 (2000), 519–521.
47. 47 Tichy, L., Freiberger, T., Zapletalova, P., et al. The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations. Eur Heart J 223 (2012), 401–408.
48. 48 Hooper, A.J., Nguyen, L.T., Burnett, J.R., et al. Genetic analysis of familial hypercholesterolaemia in Western Australia. Eur Heart J 224 (2012), 430–434.
49. 49 Humphries, S.E., Cranston, T., Allen, M., et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med (Berl) 84 (2006), 203–214.
50. 50 Klancar, G., Groselj, U., Kovac, J., et al. Universal screening for familial hypercholesterolemia in children. J Am Coll Cardiol 66 (2015), 1250–1257.
51. 51 Sharifi, M., Walus-Miarka, M., Idzior-Walus, B., et al. The genetic spectrum of familial hypercholesterolemia in south-eastern Poland. Metabolism 65 (2016), 48–53.
52. 52 Leren, T.P., Berge, K.E., Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated. PLoS One, 6, 2011, e16721.
53. 53 Kalina, A., Csaszar, A., Czeizel, A.E., et al. Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened clinically for familial hypercholesterolemia in Hungary. Eur Heart J 154 (2001), 247–251.
54. 54 Horvath, A., Savov, A., Kirov, S., et al. High frequency of the ApoB-100 R3500Q mutation in Bulgarian hypercholesterolaemic subjects. J Med Genet 38 (2001), 536–540.
55. 55 Gasparovic, J., Basistova, Z., Fabryova, L., et al. Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity?. Eur Heart J 194 (2007), e95–e107.
56. 56 Seripa, D., Gravina, C., Volpe, R., et al. Absence of apolipoprotein B3500 mutation in type 2a hyperlipoproteinemia patients and in the general population from southern Italy. J Inherit Metab Dis 22 (1999), 670–671.
57. 57 Palacios, L., Grandoso, L., Cuevas, N., et al. Molecular characterization of familial hypercholesterolemia in Spain. Eur Heart J 221 (2012), 137–142.
58. 58 Mollaki, V., Progias, P., Drogari, E., Familial hypercholesterolemia in Greek children and their families: genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum. Eur Heart J 237 (2014), 798–804.
59. 59 Real, J.T., Chaves, F.J., Ejarque, I., et al. Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients from a South European population. Eur J Hum Genet 11 (2003), 959–965.
60. 60 Bertolini, S., Pisciotta, L., Rabacchi, C., et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Eur Heart J 227 (2013), 342–348.
61. 61 Hamalainen, T., Palotie, A., Aalto-Setala, K., et al. Absence of familial defective apolipoprotein B-100 in Finnish patients with elevated serum cholesterol. Eur Heart J 82 (1990), 177–183.
62. 62 Chiou, K.R., Charng, M.J., Common mutations of familial hypercholesterolemia patients in Taiwan: characteristics and implications of migrations from southeast China. Gene 498 (2012), 100–106.
63. 63 Tai, D.Y., Pan, J.P., Lee-Chen, G.J., Identification and haplotype analysis of apolipoprotein B-100 Arg3500–>Trp mutation in hyperlipidemic Chinese. Clin Chem 44 (1998), 1659–1665.
64. 64 Wu, J.H., Lee, Y.T., Hsu, H.C., et al. Further characterization of apolipoprotein B genetic variations in Taiwanese. Hum Biol 73 (2001), 451–460.
65. 65 Yang, K.C., Su, Y.N., Shew, J.Y., et al. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J Formos Med Assoc 106 (2007), 799–807.
66. 66 Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128 (2011), S213–S256.
67. 67 Hoogeveen, R.C., Gaubatz, J.W., Sun, W., et al. Small dense LDL cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 34 (2014), 1069–1077.
68. 68 Nordestgaard, B., Chapman, M., Humphries, S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. Eur Heart J 34 (2013), 3478–3490a.
69. 69 Goldberg, A.C., Hopkins, P.N., Toth, P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5 (2011), S1–S8.